Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

OTHER 1

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Renal Insufficiency 1Osteosarcoma 1Neoplasms 1Lymphoma 1Leukemia 1

Interventions

Crizotinib 2Bone Marrow Transplantation 23-Iodobenzylguanidine 2vorasidenib 1tucatinib 1tovorafenib 1tazemetostat 1taletrectinib 1olaparib 1nirogacestat 1glucarpidase 1enzalutamide 1denileukin diftitox 1copanlisib 1balstilimab 1atezolizumab 1adagrasib 1Proton Pump Inhibitors 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1LY3023414 1Hydrocortisone 1Carboxypeptidases 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Neoplasms × glucarpidase × Clear all
NCT00481559 2014-01-17

Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

BTG International Inc.

Approved for marketing
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neoplasms, Osteosarcoma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡